Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone
- 7 April 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (7), 1440-1450
- https://doi.org/10.1200/jco.2000.18.7.1440
Abstract
PURPOSE: Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC). A prospective randomized clinical trial was designed...Keywords
This publication has 39 references indexed in Scilit:
- Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.Journal of Clinical Oncology, 1998
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.Journal of Clinical Oncology, 1997
- Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.Journal of Clinical Oncology, 1995
- Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.Journal of Clinical Oncology, 1995
- Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.Journal of Clinical Oncology, 1995
- Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1993
- Quality of life and treatment of hormone resistant metastatic prostatic cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?Journal of Clinical Oncology, 1985
- A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.Journal of Clinical Oncology, 1985